Kala’e Camarillo, a Maui-born musician with deep roots in Hawaii’s music community, has released “Sands of Old Lahaina” which earned three Nā Hōkū awards and will celebrate ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Kala Pharmaceuticals ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Arlington biotech has been ...

Kala Bio said it laid off most of its employees after receiving notice that its lender, Oxford Finance, intends to foreclose on all of its remaining assets. The move follows the biotech company's ...

Shares of KALA BIO KALA have nosedived 88.3% in a month after the company announced the failure of a mid-stage study evaluating its only clinical pipeline candidate, KPI-012, for the treatment of ...

Earlier this year, Bloomberg reported that Apple was working on a redesigned Apple Vision Pro strap as part of a wider set of upgrades to the first-generation headset. Now, a few extra details about ...

On Detroit’s Westside, Cody High School will face Pershing in the October 3rd Friday night football game. This year Cody’s homecoming game will look a bit different—in fact, the school will debut ...

Kala Bio, Inc. (NASDAQ:KALA), a biotech company with a market capitalization of $10.74 million and showing significant stock volatility, announced it received a written notice of default from Oxford ...

ARLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

Shares of Kala Bio plummeted Monday after the company said a study of its treatment for Persistent Corneal Epithelial Defect, an eye defect, missed its primary endpoints and it would stop development ...

Sept 29 (Reuters) - Kala Bio (KALA.O), opens new tab will stop developing its experimental treatment for a type of eye condition after it failed to meet the main goal in a mid-stage study, sending the ...

Kala Bio will stop developing its experimental treatment for a type of eye condition after it failed to meet the main goal in a mid-stage study, sending the drug developer's shares down 93% in ...